Newer imaging modalities to assess tumor in the prostate

Cancer Control

Volumn 11, Issue 6, 2004, Pages 353-357

  Hersh, Marla R ^a   Knapp, Edson L ^a,b   Choi, Junsung ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b East Pasco Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DOPPLER FLOWMETRY; HUMAN; IMAGING SYSTEM; LITERATURE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ULTRASOUND;

EID: 10044270845     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480401100602     Document Type: Review

References (23)

1. Engelbrecht MR, Barentsz JO, Jager GJ, et al. Prostate cancer staging using imaging. BJU Int. 2000;86(suppl 1):123-134.
2. Borley N, Fabrin K, Sriprasad S, et al. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT. Scand J Urol Nephrol. 2003;37:382-386.
3. Purohit RS, Shinohara K, Meng MV, et al. Imaging clinically localized prostate cancer. Urol Clin North Am. 2003;30:279-293.
4. Wilkinson S, Chodak G. The role of 111-indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol. 2004;172:133-136.
5. D'Amico AV, Whittington R, Malkowicz SB, et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organconfined prostate cancer. J Clin Oncol. 1996;14:1770-1777.
6. Engelbrecht MR, Jager GJ, Laheij RJ, et al. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol. 2002;12:2294-2302. Epub 2002Apr 19.
7. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal pelvic phased-array coils. Radiology. 1994;193:703-709.
8. Langlotz C, Schnall M, Pollack H, et al. Staging of prostate cancer: accuracy of MR imaging. Radiology. 1995;194:645-046.
9. Plawker MW, Fleisher JM, Vapnek EM, et al. Current trends in prostate cancer diagnosis and staging among United States urologists. J Urol. 1997;158:1853-1858.
10. Jager GJ, Severens JL, Thornbury JR, et al. Prostate cancer staging: should MR imaging be used? A decision analytic approach. Radiology. 2000;215:445-451.
11. Engelbrecht MR, Jager GJ, Severens JL, et al. Patient selection for magnetic resonance imaging of prostate cancer. Eur Urol. 2001;40:300-307.
12. Cornud F, Flam T, Chauveine L, et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology. 2002;224:203-210.
13. Kurhanewicz J, Swanson MG, Nelson SJ, et al. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002;16: 451-463.
14. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging. Clinicopathologic study. Radiology. 1999;213:473-480.
15. Vigneron DB, Males R, Hricak H, et al. Prostate cancer: correlation of 3D MRSI metabolite levels with histologic grade. Proceedings of the Radiological Society of North America. Chicago. Ill: 1998;181.
16. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499. Erratum in: N Engl J Med. 2003; 349:1010.
17. Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 2003;229:248-254. Epub 2003 Aug 27.
18. Jennings D, Hatton BN, Guo J, et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia. 2002;4:255-262.
19. Shvarts O, Han K, Seltzer M, et al. Positron emission tomography in urologic oncology. Cancer Control. 2002;9:335-342.
20. Hara T, Kosaka N, Kishi H, et al. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990-995.
21. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963-969.
22. Cornud F, Hamida K, Flam T, et al. Endorectal color Doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. AJR Am J Roentgenol. 2000;175:1161-1168.
23. Langlotz C, Schnall M, Pollack H, et al. Staging of prostatic cancer: accuracy of MR imaging. Radiology. 1995;194:645-646; discussion 647-648.